Parathyroid Gland Function in Primary Aldosteronism

 

 Buy Article Permissions and Reprints

Abstract

Primary aldosteronism (PA) is the most frequent cause of secondary arterial hypertension. Beyond its effects on intravascular volume and blood pressure, PA causes metabolic alterations and a higher cardiovascular morbidity, which is reduced by PA-directed therapy. Experimental studies demonstrated that mineralocorticoid excess may also influence mineral homeostasis. A role in cardiovascular disease has also been attributed to parathyroid hormone (PTH). Increasing evidence supports a bidirectional interaction between aldosterone and PTH.

Primary hyperparathyroidism is associated with arterial hypertension and an increased cardiovascular morbidity and mortality, which might be associated to higher aldosterone values; parathyreoidectomy results in lowered aldosterone and blood pressure levels. PA leads to secondary hyperparathyroidism, which is reversible by PA-directed therapy. A lower bone mineral density and a higher fracture rate were also shown to be reversible by PA-directed therapy. There is a suspicion of a bidirectional interaction between aldosterone and PTH, which might lead to a higher cardiovascular risk. There are more and more reports about coincident PA and primary hyperparathyroidism. From a pathophysiologic point of view this constellation is best characterized as tertiary hyperparathyroidism. Future aspects should further clarify the extent of these endocrine interactions and analyze the influence of this interplay on cardiovascular morbidity and mortality and bone health.

Publication History

Received: 15 August 2015

Accepted: 06 November 2015

Article published online:
14 December 2015

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
  CrossrefPubMedGoogle Scholar
• 2 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
  CrossrefPubMedGoogle Scholar
• 3 Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension 2012; 60: 618-624
  CrossrefPubMedGoogle Scholar
• 4 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
  CrossrefPubMedGoogle Scholar
• 5 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
  CrossrefPubMedGoogle Scholar
• 6 Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004; 287: H2023-H2026
  CrossrefPubMedGoogle Scholar
• 7 Runyan AL, Chhokar VS, Sun Y, Bhattacharya SK, Runyan JW, Weber KT. Bone loss in rats with aldosteronism. Am J Med Sci 2005; 330: 1-7
  CrossrefPubMedGoogle Scholar
• 8 Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, Khan BQ, Gupta M, Ahmad K, Khouzam RN, Dishmon DA, Nesheiwat JP, Hajjar MA, Chishti WA, Nasser W, Khan M, Womack CR, Cho T, Haskin AR, Weber KT. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008; 52: 135-138
  CrossrefPubMedGoogle Scholar
• 9 van Ballegooijen AJ, Reinders I, Visser M, Dekker JM, Nijpels G, Stehouwer CD, Pilz S, Brouwer IA. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 2013; 98: E638-E645
  CrossrefPubMedGoogle Scholar
• 10 Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, Gaksch M, Grubler M, Fahrleitner-Pammer A, Mrak P, Toplak H, Kraigher-Krainer E, Marz W, Pilz S. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 2014; 63: 20-31
  CrossrefPubMedGoogle Scholar
• 11 Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: a clinically relevant research field. Hypertension 2014; 63: 212-214
  CrossrefPubMedGoogle Scholar
• 12 Brown JM, Vaidya A. Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes 2014; 21: 193-201
  CrossrefPubMedGoogle Scholar
• 13 Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage?. Hypertens Res 2011; 34: 286-288
  CrossrefPubMedGoogle Scholar
• 14 Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580
  CrossrefPubMedGoogle Scholar
• 15 Zhang C, Miller CL, Brown EM, Yang JJ. The calcium sensing receptor: from calcium sensing to signaling. Sci China Life Sci 2015; 58: 14-27
  CrossrefPubMedGoogle Scholar
• 16 Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers S, Conigrave AD, Hampson DR. Calcium-sensing receptor modulates cell adhesion and migration via integrins. J Biol Chem 2011; 286: 40922-40933
  CrossrefPubMedGoogle Scholar
• 17 Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71
  CrossrefPubMedGoogle Scholar
• 18 Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84: 489-539
  CrossrefPubMedGoogle Scholar
• 19 Boulkroun S, Fernandes-Rosa FL, Zennaro MC. Molecular and cellular mechanisms of aldosterone producing adenoma development. Front Endocrinol 2015; 6: 95
  CrossrefPubMedGoogle Scholar
• 20 Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572-581
  CrossrefPubMedGoogle Scholar
• 21 Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol 2010; 25: 2241-2245
  CrossrefPubMedGoogle Scholar
• 22 Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239-297
  CrossrefPubMedGoogle Scholar
• 23 Brown EM. The extracellular Ca2+-sensing receptor: central mediator of systemic calcium homeostasis. Ann Rev Nutr 2000; 20: 507-533
  CrossrefPubMedGoogle Scholar
• 24 Mateus-Hamdan L, Beauchet O, Bouvard B, Legrand E, Fantino B, Annweiler C. High parathyroid hormone, but not low vitamin D concentrations, expose elderly inpatients to hypertension. Geriatr Gerontol Int 2013; 13: 783-791
  CrossrefPubMedGoogle Scholar
• 25 Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, Siscovick D, Kestenbaum B. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011; 58: 1021-1028
  CrossrefPubMedGoogle Scholar
• 26 Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, Marz W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31: 1591-1598
  CrossrefPubMedGoogle Scholar
• 27 Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K, Arnlov J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119: 2765-2771
  CrossrefPubMedGoogle Scholar
• 28 Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, A crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther 2013; 27: 161-170
  CrossrefPubMedGoogle Scholar
• 29 Monego G, Arena V, Pasquini S, Stigliano E, Fiaccavento R, Leone O, Arpesella G, Potena L, Ranelletti FO, Di Nardo P, Capelli A. Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. Basic Res Cardiol 2009; 104: 427-434
  CrossrefPubMedGoogle Scholar
• 30 Yusuf J, Khan MU, Cheema Y, Bhattacharya SK, Weber KT. Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones. Prog Cardiovasc Dis 2012; 55: 77-86
  CrossrefPubMedGoogle Scholar
• 31 Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med 2002; 251: 476-483
  CrossrefPubMedGoogle Scholar
• 32 Lind L, Ridefelt P, Rastad J, Akerstrom G, Ljunghall S. Relationship between abnormal regulation of cytoplasmic calcium and elevated blood pressure in patients with primary hyperparathyroidism. J Hum Hypertens 1994; 8: 113-118
  PubMedGoogle Scholar
• 33 Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, Petramala L, Celi M, Minisola S, D’Erasmo E, Mazzuoli GF. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens 2005; 19: 901-906
  CrossrefPubMedGoogle Scholar
• 34 Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery 2000; 128: 895-902
  CrossrefPubMedGoogle Scholar
• 35 Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003; 27: 216-222
  CrossrefPubMedGoogle Scholar
• 36 Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50: 321-328
  CrossrefPubMedGoogle Scholar
• 37 Stefenelli T, Abela C, Frank H, Koller-Strametz J, Niederle B. Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery 1997; 121: 157-161
  CrossrefPubMedGoogle Scholar
• 38 Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism – an update. Eur J Clin Invest 1998; 28: 271-276
  CrossrefPubMedGoogle Scholar
• 39 Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe – nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 (Suppl. 02) N68-N74
  PubMedGoogle Scholar
• 40 Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the parathyroid epidemiology and audit research study (PEARS). Clin Endocrinol (Oxf) 2011; 75: 169-176
  CrossrefPubMedGoogle Scholar
• 41 Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997; 15: 1271-1276
  CrossrefPubMedGoogle Scholar
• 42 Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, Corbetti F, Montisci R, Famoso G, Bellu R, Luscher TF, Iliceto S, Tona F. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 2012; 126: 1031-1039
  CrossrefPubMedGoogle Scholar
• 43 Brown J, de Boer IH, Robinson-Cohen C, Siscovick DS, Kestenbaum B, Allison M, Vaidya A. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab 2015; 100: 490-499
  CrossrefPubMedGoogle Scholar
• 44 Fischer E, Hannemann A, Rettig R, Lieb W, Nauck M, Pallauf A, Bildingmaier M, Beuschlein F, Wallaschofski H, Reincke M. A high aldosterone to Renin ratio is associated with high serum parathyroid hormone concentrations in the general population. J Clin Endocrinol Metab 2014; 99: 965-971
  CrossrefPubMedGoogle Scholar
• 45 Tomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H, Kapl M, Grammer T, Ritz E, Horina JH, Kleber ME, Pieske B, Kraigher-Krainer E, Hartaigh BO, Toplak H, van Ballegooijen AJ, Amrein K, Fahrleitner-Pammer A, Marz W. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol 2015; 184: 710-716
  CrossrefPubMedGoogle Scholar
• 46 Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, Ayav A, Weryha G, Mirallie E, Bresler L. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 2009; 146: 1035-1041
  CrossrefPubMedGoogle Scholar
• 47 Kovacs L, Goth MI, Szabolcs I, Dohan O, Ferencz A, Szilagyi G. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 1998; 138: 543-547
  CrossrefPubMedGoogle Scholar
• 48 Pacifici R, Perry 3rd HM, Shieber W, Biglieri E, Droke DM, Avioli LV. Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism. Calcif Tissue Int 1987; 41: 119-123
  CrossrefPubMedGoogle Scholar
• 49 Sotornik I, Stribrna J, Hronova J, Kocandrle V, Janata V, Taborsky P, Bultasova H, Zichova M. Changes in plasma renin and aldosterone after parathyroidectomy in patients with hyperparathyroidism. Casopis Lekaru Ceskych 1993; 132: 45-49
  PubMedGoogle Scholar
• 50 Bernini G, Moretti A, Lonzi S, Bendinelli C, Miccoli P, Salvetti A. Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery. Metabolism 1999; 48: 298-300
  CrossrefPubMedGoogle Scholar
• 51 Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski AH. Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 1988; 6: 747-752
  CrossrefPubMedGoogle Scholar
• 52 Salahudeen AK, Thomas TH, Sellars L, Tapster S, Keavey P, Farndon JR, Johnston ID, Wilkinson R. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci (Lond) 1989; 76: 289-296
  CrossrefPubMedGoogle Scholar
• 53 Rosa J, Raska Jr I, Wichterle D, Petrak O, Strauch B, Somloova Z, Zelinka T, Holaj R, Widimsky Jr J. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res 2011; 34: 296-300
  CrossrefPubMedGoogle Scholar
• 54 Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 3326-3330
  CrossrefPubMedGoogle Scholar
• 55 Pilz S, Tomaschitz A, Marz W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int 2010; 87: 373-374
  CrossrefPubMedGoogle Scholar
• 56 Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, Marz W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 2012; 97: E75-E79
  CrossrefPubMedGoogle Scholar
• 57 Tomaschitz A, Fahrleitner-Pammer A, Pieske B, Verheyen N, Amrein K, Ritz E, Kienreich K, Horina JH, Schmidt A, Kraigher-Krainer E, Colantonio C, Meinitzer A, Pilz S. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord 2012; 12: 19
  CrossrefPubMedGoogle Scholar
• 58 Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985; 78: 385-390
  CrossrefPubMedGoogle Scholar
• 59 Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, De Caro R, Calo LA, Pessina AC, Rossi GP. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens 2012; 30: 390-395
  CrossrefPubMedGoogle Scholar
• 60 Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995; 8: 884-893
  CrossrefPubMedGoogle Scholar
• 61 Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M, Giacchetti G. Bone health and aldosterone excess. Osteoporos Int 2013; 24: 2801-2807
  CrossrefPubMedGoogle Scholar
• 62 Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, Guglielmi G, Desina G, Eller-Vainicher C, Beck-Peccoz P, Scillitani A, Chiodini I. Bone involvement in aldosteronism. J Bone Miner Res 2012; 27: 2217-2222
  CrossrefPubMedGoogle Scholar
• 63 Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calo LA, Frigo AC, Fassina A, Pessina AC. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 2012; 60: 431-436
  CrossrefPubMedGoogle Scholar
• 64 Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, Reincke M, Quinkler M. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 2014; 99: E1035-E1039
  CrossrefPubMedGoogle Scholar
• 65 Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, Vaidya A. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension 2014; 63: 273-280
  CrossrefPubMedGoogle Scholar
• 66 Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001; 16: 1496-1504
  CrossrefPubMedGoogle Scholar
• 67 Gupta M, Cheung CL, Hsu YH, Demissie S, Cupples LA, Kiel DP, Karasik D. Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res 2011; 26: 1261-1271
  CrossrefPubMedGoogle Scholar
• 68 Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 2011; 58: 341-346
  CrossrefPubMedGoogle Scholar
• 69 Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 2001; 280: E209-E213
  CrossrefPubMedGoogle Scholar
• 70 Olgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab 1994; 20: 309-314
  PubMedGoogle Scholar
• 71 Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol 1987; 112: 431-437
  CrossrefPubMedGoogle Scholar
• 72 Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology 1991; 129: 489-495
  CrossrefPubMedGoogle Scholar
• 73 Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab 1992; 75: 988-992
  PubMedGoogle Scholar
• 74 Fallo F, Rocco S, Pagotto U, Zangari M, Luisetto G, Mantero F. Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. J Hypertension 1989; (Suppl. 07) S192-S193
  CrossrefPubMedGoogle Scholar
• 75 Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology 1991; 129: 1233-1242
  CrossrefPubMedGoogle Scholar
• 76 Saussine C, Judes C, Massfelder T, Musso MJ, Simeoni U, Hannedouche T, Helwig JJ. Stimulatory action of parathyroid hormone on renin secretion in vitro: a study using isolated rat kidney, isolated rabbit glomeruli and superfused dispersed rat juxtaglomerular cells. Clin Sci (Lond) 1993; 84: 11-19
  CrossrefPubMedGoogle Scholar
• 77 Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2: 360-370
  PubMedGoogle Scholar
• 78 Rafferty B, Zanelli JM, Rosenblatt M, Schulster D. Corticosteroidogenesis and adenosine 3′, 5′- monophosphate production by the amino-terminal (1–34) fragment of human parathyroid hormone in rat adrenocortical cells. Endocrinology 1983; 113: 1036-1042
  CrossrefPubMedGoogle Scholar
• 79 Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid “escape” in man. Kidney Int 1972; 2: 279-286
  CrossrefPubMedGoogle Scholar
• 80 Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C, Casoli MC, Regolisti G. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens 1998; 11: 8-13
  CrossrefPubMedGoogle Scholar
• 81 Kamalov G, Bhattacharya SK, Weber KT. Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol 2010; 56: 320-328
  CrossrefPubMedGoogle Scholar
• 82 Abe H, Kubota K, Noie T, Kimura W, Makuuchi M. A rare combination consisting of primary hyperaldosteronism and glucagonoma. Am J Gastroenterol 1999; 94: 1397-1401
  CrossrefPubMedGoogle Scholar
• 83 Berbarie RF, Emmett M, Breslau NA. Quiz page. Secondary hypertension with contralateral pheochromocytoma and aldosteronoma. Am J Kidney Dis 2005; 46 A51 e51-e53
  PubMedGoogle Scholar
• 84 Beckers A, Abs R, Willems PJ, van der Auwera B, Kovacs K, Reznik M, Stevenaert A. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J Clin Endocrinol Metab 1992; 75: 564-570
  PubMedGoogle Scholar
• 85 Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad Med J 1980; 56: 45-47
  CrossrefPubMedGoogle Scholar
• 86 Barkan A, Marilus R, Winkelsberg G, Yeshurun D, Blum I. Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-year-old woman. J Clin Endocrinol Metab 1980; 51: 144-147
  CrossrefPubMedGoogle Scholar
• 87 Honda M, Tsukada T, Horiuchi T, Tanaka R, Yamaguchi K, Obara T, Miyakawa H, Yamaji T, Ishibashi M. Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 2004; 43: 310-314
  CrossrefPubMedGoogle Scholar
• 88 Chau K, Holmes D, Melck A, Chan-Yan C. Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma. Am J Hypertens 2015; 28: 280-282
  CrossrefPubMedGoogle Scholar
• 89 Molina-Ayala M, Ramirez-Renteria C, Manguilar-Leon A, Paul-Gaytan P, Ferreira-Hermosillo A. A rare presentation of primary hyperparathyroidism with concurrent aldosterone-producing adrenal carcinoma. Case Rep Endocrinol 2015; 910984
  PubMedGoogle Scholar
• 90 Petramala L, Savoriti C, Zinnamosca L, Marinelli C, Settevendemmie A, Calvieri C, Catani M, Letizia C. Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders. Intern Med 2013; 52: 2071-2075
  CrossrefPubMedGoogle Scholar
• 91 Concistre A, Petramala L, Zinnamosca L, Settevendemmie A, Corpaci F, Marinelli C, Tonnarini GF, D’Ermo G, De Toma G, Letizia C. Primary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre. Eur Rev Med Pharmacol Sci 2015; 19: 971-976
  PubMedGoogle Scholar